PRNP and prion disease: Whilst small molecules that were promising in pre-clinical studies proved not to be effective in trials, immunotherapeutic and antisense oligonucleotide approaches to developing disease-modifying therapeutics for prion disease have shown substantial promise at pre-clinical stages [6–11], and passive immunotherapy with a humanised anti-PrPC monoclonal antibody is being clinically evaluated [12].